Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer
The intermediate-risk category of papillary thyroid cancer (PTC) comprises heterogeneous patients within a wide range of stages and varied care management. Understanding the risk features of recurrence observed after the initial therapy should be emphasized. We aimed to evaluate the prognostic signi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-05-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/12/5/1254 |
| _version_ | 1797500423366508544 |
|---|---|
| author | Xi Jia Yuanbo Wang Lulu Yang Kun Fan Runyi Tao Hui Liu Xiaobao Yao Aimin Yang Guangjian Zhang Rui Gao |
| author_facet | Xi Jia Yuanbo Wang Lulu Yang Kun Fan Runyi Tao Hui Liu Xiaobao Yao Aimin Yang Guangjian Zhang Rui Gao |
| author_sort | Xi Jia |
| collection | DOAJ |
| description | The intermediate-risk category of papillary thyroid cancer (PTC) comprises heterogeneous patients within a wide range of stages and varied care management. Understanding the risk features of recurrence observed after the initial therapy should be emphasized. We aimed to evaluate the prognostic significance of radioactive iodine-avid lymph nodes observed during the initial treatment of patients with PTC that were considered to be at intermediate risk. Data on patients with intermediate-risk PTC treated from 2012 to 2018 were retrospectively reviewed. Post-therapeutic SPECT/CT (Rx SPECT/CT) was evaluated in the enrolled patients. The clinical, pathologic, and incidence of radioiodine-avid (RAI-avid) lymph node metastasis (mLN) on Rx SPECT/CT were reviewed, and risk factors related to recurrent disease were analyzed. After a median follow-up of 37.26 (30.90, 46.33) months, structural persistent/recurrent disease was detected in 9.81% (36/367) of patients with intermediate-risk tumors. The incidence of recurrence was higher in patients who demonstrated RAI-avid mLN after the initial therapy than in those who did not (<i>p</i> < 0.001). In a multivariate Cox proportional hazard regression analysis, RAI-avid mLN appeared to be a robust risk factor for recurrent disease after the initial therapy (HR: 8.967, 95% CI: 3.433–23.421, <i>p</i> = 0.000). RAI-avid mLN is a significant risk factor for recurrent intermediate-risk PTC after the initial treatment. |
| first_indexed | 2024-03-10T03:01:41Z |
| format | Article |
| id | doaj.art-2f8138910ff144f59687f4486a6c1f30 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T03:01:41Z |
| publishDate | 2022-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-2f8138910ff144f59687f4486a6c1f302023-11-23T10:41:34ZengMDPI AGDiagnostics2075-44182022-05-01125125410.3390/diagnostics12051254Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid CancerXi Jia0Yuanbo Wang1Lulu Yang2Kun Fan3Runyi Tao4Hui Liu5Xiaobao Yao6Aimin Yang7Guangjian Zhang8Rui Gao9Department of Nuclear Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of Biobank, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of Otorhinolaryngology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, ChinaThe intermediate-risk category of papillary thyroid cancer (PTC) comprises heterogeneous patients within a wide range of stages and varied care management. Understanding the risk features of recurrence observed after the initial therapy should be emphasized. We aimed to evaluate the prognostic significance of radioactive iodine-avid lymph nodes observed during the initial treatment of patients with PTC that were considered to be at intermediate risk. Data on patients with intermediate-risk PTC treated from 2012 to 2018 were retrospectively reviewed. Post-therapeutic SPECT/CT (Rx SPECT/CT) was evaluated in the enrolled patients. The clinical, pathologic, and incidence of radioiodine-avid (RAI-avid) lymph node metastasis (mLN) on Rx SPECT/CT were reviewed, and risk factors related to recurrent disease were analyzed. After a median follow-up of 37.26 (30.90, 46.33) months, structural persistent/recurrent disease was detected in 9.81% (36/367) of patients with intermediate-risk tumors. The incidence of recurrence was higher in patients who demonstrated RAI-avid mLN after the initial therapy than in those who did not (<i>p</i> < 0.001). In a multivariate Cox proportional hazard regression analysis, RAI-avid mLN appeared to be a robust risk factor for recurrent disease after the initial therapy (HR: 8.967, 95% CI: 3.433–23.421, <i>p</i> = 0.000). RAI-avid mLN is a significant risk factor for recurrent intermediate-risk PTC after the initial treatment.https://www.mdpi.com/2075-4418/12/5/1254radionuclide imagingpersistentrecurrenceintermediate riskpapillary thyroid cancer |
| spellingShingle | Xi Jia Yuanbo Wang Lulu Yang Kun Fan Runyi Tao Hui Liu Xiaobao Yao Aimin Yang Guangjian Zhang Rui Gao Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer Diagnostics radionuclide imaging persistent recurrence intermediate risk papillary thyroid cancer |
| title | Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer |
| title_full | Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer |
| title_fullStr | Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer |
| title_full_unstemmed | Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer |
| title_short | Lymph Node Metastases Identified at the Post-Ablation 131I SPECT/CT Scan Is a Prognostic Factor of Intermediate-Risk Papillary Thyroid Cancer |
| title_sort | lymph node metastases identified at the post ablation 131i spect ct scan is a prognostic factor of intermediate risk papillary thyroid cancer |
| topic | radionuclide imaging persistent recurrence intermediate risk papillary thyroid cancer |
| url | https://www.mdpi.com/2075-4418/12/5/1254 |
| work_keys_str_mv | AT xijia lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer AT yuanbowang lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer AT luluyang lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer AT kunfan lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer AT runyitao lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer AT huiliu lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer AT xiaobaoyao lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer AT aiminyang lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer AT guangjianzhang lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer AT ruigao lymphnodemetastasesidentifiedatthepostablation131ispectctscanisaprognosticfactorofintermediateriskpapillarythyroidcancer |